Brainchild Bio Launches to Expedite CAR T-cell Therapy Development
A new biotech company called BrainChild Bio was created by Seattle Children’s Clinic. The company’s focus is a CAR T-cell therapy initiative aimed at treating malignancies in the central nervous system, specifically tumors like glioblastoma.
Funded by investments from Seattle Children’s Hospital, BrainChild Bio will hold four studies to gauge the therapy’s efficacy and potential weaknesses.
“BrainChild Bio is founded with a mission to bring the best ideas forward to push the bounds of scientific discovery in service of children with cancer,” said Dr. Michael Jensen, the new company’s lead science executive. “We are steadfast in our commitment to cracking the code of harnessing CAR T-cell technology in CNS tumors and we are uniquely positioned to do so.”